Association of Cancer with the Risk of Developing Hypertension

Overview

Journal Eur Heart J Qual Care Clin Outcomes

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2023 Jun 15

PMID 37321962

Authors

Hajime Nagasawa

Hidehiro Kaneko

Yuta Suzuki

Akira Okada

Katsuhito Fujiu

Norifumi Takeda

Hiroyuki Morita

Akira Nishiyama

Yuichiro Yano

Koichi Node

Anthony J Viera

Robert M Carey

Suzanne Oparil

Hideo Yasunaga

Rhian M Touyz

Issei Komuro

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Although the importance of hypertension in patients with cancer is widely recognized, little is known about the risk of developing hypertension in patients with a history of cancer.

Methods And Results: This retrospective observational cohort study analysed data from the JMDC Claims Database between 2005 and 2022, including 78 162 patients with a history of cancer and 3692 654 individuals without cancer. The primary endpoint was the incidence of hypertension.During a mean follow-up period of 1208 ± 966 days, 311 197 participants developed hypertension. The incidence of hypertension was 364.6 [95% confidence interval (CI) 357.0-372.2] per 10 000 person-years among those with a history of cancer, and 247.2 (95% CI 246.3-248.1) per 10 000 person-years in those without cancer. Individuals with a history of cancer had an elevated risk of developing hypertension, according to multivariable Cox regression analyses [hazard ratio (HR) 1.17, 95% CI 1.15-1.20]. Both cancer patients requiring active antineoplastic therapy (HR 2.01, 95% CI 1.85-2.20), and those who did not require active antineoplastic therapy (HR 1.14, 95% CI 1.12-1.17) had an increased risk of hypertension. A multitude of sensitivity analyses confirmed the robustness of the relationship between cancer and incident hypertension. Patients with certain types of cancer were found to have a higher risk of developing hypertension than those without cancer, with varying risks dependent on the type of cancer.

Conclusion: Our analysis of a nationwide epidemiological database revealed that individuals with a history of cancer have a higher risk of developing hypertension, and this finding applies to both cancer patients who require active antineoplastic therapy and those who do not.

Citing Articles

Current Status and Future Perspective of Onco-Hypertension.

Azegami T, Kaneko H, Minegishi S, Suzuki Y, Morita H, Fujiu K Am J Hypertens. 2024; 38(1):1-6.

PMID: 39078615 PMC: 11646863. DOI: 10.1093/ajh/hpae099.

References

Aloisio K, Swanson S, Micali N, Field A, Horton N . Analysis of partially observed clustered data using generalized estimating equations and multiple imputation. Stata J. 2015; 14(4):863-883. PMC: 4306281. View

Seretis A, Cividini S, Markozannes G, Tseretopoulou X, Lopez D, Ntzani E . Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019; 9(1):8565. PMC: 6561976. DOI: 10.1038/s41598-019-45014-4. View

Stojanovic M, Goldner B, Ivkovic D . Renal cell carcinoma and arterial hypertension. Clin Exp Nephrol. 2009; 13(4):295-299. DOI: 10.1007/s10157-008-0122-x. View

Eremina V, Jefferson J, Kowalewska J, Hochster H, Haas M, Weisstuch J . VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11):1129-36. PMC: 3030578. DOI: 10.1056/NEJMoa0707330. View

Fraeman K, Nordstrom B, Luo W, Landis S, Shantakumar S . Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2014; 2013:379252. PMC: 3876828. DOI: 10.1155/2013/379252. View

Takahashi K, Totsune K, Kitamuro T, Sone M, Murakami O, Shibahara S . Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. Clin Sci (Lond). 2002; 103 Suppl 48:35S-38S. DOI: 10.1042/CS103S035S. View

Hara K, Tomio J, Svensson T, Ohkuma R, Svensson A, Yamazaki T . Association measures of claims-based algorithms for common chronic conditions were assessed using regularly collected data in Japan. J Clin Epidemiol. 2018; 99:84-95. DOI: 10.1016/j.jclinepi.2018.03.004. View

Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G . Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012; 59(4):802-10. DOI: 10.1161/HYPERTENSIONAHA.111.189258. View

Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T . Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. Circulation. 2021; 143(23):2244-2253. DOI: 10.1161/CIRCULATIONAHA.120.052624. View

10.

van Dorst D, Dobbin S, Neves K, Herrmann J, Herrmann S, Versmissen J . Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res. 2021; 128(7):1040-1061. PMC: 8011349. DOI: 10.1161/CIRCRESAHA.121.318051. View

11.

Fujihara K, Yamada-Harada M, Matsubayashi Y, Kitazawa M, Yamamoto M, Yaguchi Y . Accuracy of Japanese claims data in identifying diabetes-related complications. Pharmacoepidemiol Drug Saf. 2021; 30(5):594-601. DOI: 10.1002/pds.5213. View

12.

Kaneko H, Yano Y, Lee H, Lee H, Okada A, Itoh H . Medication-Naïve Blood Pressure and Incident Cancers: Analysis of 2 Nationwide Population-Based Databases. Am J Hypertens. 2022; 35(8):731-739. DOI: 10.1093/ajh/hpac054. View

13.

Shigemi D, Morishima T, Yamana H, Yasunaga H, Miyashiro I . Validity of initial cancer diagnoses in the Diagnosis Procedure Combination data in Japan. Cancer Epidemiol. 2021; 74:102016. DOI: 10.1016/j.canep.2021.102016. View

14.

Kew M, Leckie B, Greeff M . Arterial hypertension as a paraneoplastic phenomenon in hepatocellular carcinoma. Arch Intern Med. 1989; 149(9):2111-3. View

15.

Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H . Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017; 27(10):476-482. PMC: 5602797. DOI: 10.1016/j.je.2016.09.009. View

16.

Cohen J, Brown N, Brown S, Dent S, van Dorst D, Herrmann S . Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023; 80(3):e46-e57. PMC: 10602651. DOI: 10.1161/HYP.0000000000000224. View

17.

Kaneko H, Itoh H, Kamon T, Fujiu K, Morita K, Michihata N . Association of Cardiovascular Health Metrics With Subsequent Cardiovascular Disease in Young Adults. J Am Coll Cardiol. 2020; 76(20):2414-2416. DOI: 10.1016/j.jacc.2020.09.545. View

18.

Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N . Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. Am J Nephrol. 2022; 53(4):307-315. PMC: 9216314. DOI: 10.1159/000522280. View

19.

Neves K, Rios F, van der Mey L, Alves-Lopes R, Cameron A, Volpe M . VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. Hypertension. 2018; 71(4):638-647. DOI: 10.1161/HYPERTENSIONAHA.117.10490. View

20.

Christakoudi S, Kakourou A, Markozannes G, Tzoulaki I, Weiderpass E, Brennan P . Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2019; 146(10):2680-2693. PMC: 7115826. DOI: 10.1002/ijc.32576. View